Agenus (NASDAQ:AGEN) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

Agenus Inc. (NASDAQ:AGEN - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.57 and traded as high as $6.33. Agenus shares last traded at $5.88, with a volume of 872,861 shares traded.

Analyst Upgrades and Downgrades

AGEN has been the topic of several analyst reports. HC Wainwright raised shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price on the stock in a report on Wednesday, June 4th. Wall Street Zen raised Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Robert W. Baird boosted their target price on Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a report on Wednesday, June 4th. Finally, B. Riley reissued a "buy" rating on shares of Agenus in a report on Monday, April 21st.

Agenus Trading Down 2.9%

The business's fifty day simple moving average is $5.26 and its 200 day simple moving average is $3.62. The stock has a market cap of $146.96 million, a P/E ratio of -0.62 and a beta of 1.51.

Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. On average, analysts predict that Agenus Inc. will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several hedge funds have recently bought and sold shares of AGEN. Bank of Montreal Can acquired a new stake in Agenus during the 4th quarter worth approximately $69,000. Barclays PLC grew its stake in shares of Agenus by 17.7% during the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock worth $90,000 after acquiring an additional 4,924 shares in the last quarter. Gilead Sciences Inc. bought a new position in shares of Agenus during the 4th quarter worth approximately $635,000. Northern Trust Corp grew its stake in shares of Agenus by 14.8% during the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock worth $572,000 after acquiring an additional 26,870 shares in the last quarter. Finally, B. Riley Financial Inc. bought a new position in shares of Agenus during the 4th quarter worth approximately $2,074,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.